Australian Pharmaceutical Industries wants to merge with rival Sigma Healthcare

Australian Pharmaceutical Industries Ltd (ASX:API) wants to merge with rival Sigma Healthcare Ltd (ASX:SIG). Should you invest in either company?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sigma Healthcare Ltd (ASX: SIG) share price has been placed in a trading halt this morning after rival Australian Pharmaceutical Industries Ltd (ASX: API) announced that it has acquired a 12.95% stake in the company and made a merger proposal.

According to the release, Australian Pharmaceutical Industries has made an offer to merge the companies with a cooperative approach so that Sigma shareholders will receive the equivalent of 68.6 cents for every share they own.

This offer comprises 23 cents per share in cash and 0.31 Australian Pharmaceutical Industries for every Sigma share. Sigma's shares last closed at 40.5 cents, meaning this offer equates to a premium of 69%.

If the offer were to be accepted and completed successfully, Australian Pharmaceutical Industries shareholders would own approximately 63% of the combined entity, with Sigma shareholders owning the remaining 37%.

Why is Australian Pharmaceutical Industries interested in merging?

Australian Pharmaceutical Industries' chairman, Mark Smith, explained that its board believes the merger will deliver significant benefits to both groups of shareholders, pharmacists, and customers.

He said: "A combined entity would create greater efficiencies in the wholesaling business to the ongoing benefit of all shareholders. This, in turn, would enable the combined business to provide greater assistance to pharmacists as they respond to current regulatory impacts and increasing retail competition, enabling a stronger, viable community pharmacy industry."

He also believes that its scale and volume would create a stronger business model in the future and expects meaningful synergies.

The release explains that Australian Pharmaceutical Industries estimates that the acquisition will deliver annualised pro-forma gross cost savings from pharmacy distribution and corporate functions of $60 million by year three of the merger. It is also expected to be immediately accretive to earnings per share.

Should you buy Australian Pharmaceutical Industries shares?

I think that this is a great idea by Australian Pharmaceutical Industries and believe the merged entity would be an attractive investment option. However, I think it's a touch soon to invest and would suggest investors wait to see how things develop in the coming days.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Share Market News

Down 90% from its 2021 peak, can IDP Education shares turn around?

Is this beaten down stock a buy? Let's find out.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Thursday

Will the market continue to rise? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Broker Notes

The smartest Australian stocks to buy with $250 right now

$250 to invest? Check out these stocks that brokers rate as buys.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Share Gainers

2 ASX All Ords stocks that would already have more than doubled your money this year

These ASX All Ords stocks have gained 126% and 145% year to date. But how?

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Broker Notes

1 magnificent Aussie stock down 23% to buy and hold forever

Let's see why this could be a top share to buy while it is down.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an historic day for the ASX, with the market setting a new record.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Bell Potter says this ASX 200 stock can rise 100%+

Let's see which stock the broker is tipping as a buy to clients.

Read more »